| Document |
Document Title |
|
WO/1994/018225A1 |
This invention provides compounds, compositions thereof, and methods of using said compounds and compositions in treating hypercholesterolemia in a mammal. Compounds of this invention have been shown to inhibit the biosynthesis of choles...
|
|
WO/1994/014833A2 |
The present invention relates to certain substituted 17beta-substituted carbonyl-6-azaandrost-4-en-3-ones of formula (I), wherein R1 and R2 i) are independently hydrogen or lower alkyl and the bond between the carbons bearing R1 and R2 i...
|
|
WO/1994/014452A1 |
17beta-N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en
-3-ones of formula (I) wherein R1 is selected from hydrogen, methyl and ethyl and R2 is a straight or branched chain alkyl, cycloalkyl, aralkyl of from 1-12 carbons, or monocyc...
|
|
WO/1994/013691A1 |
Compounds of general formula (A), wherein the carbon-carbon bond at the 1-2-positions can be simple or double; X is oxygen or sulfur; RI is hydrogen or linear or branched C1-C4 alkyl; RII and RIII, when X is oxygen, are respectively: -CH...
|
|
WO/1994/011387A2 |
Disclosed is a new process for producing finasteride which involves reacting the magnesium halide salt of 17beta-carboalkoxy-4-aza-5alpha-androst-1-en-3-one with t-butylamino magnesium halide, present in at least a 2:1 molar ratio to the...
|
|
WO/1994/011385A1 |
Invented are novel 17alpha-acyl steroidal 5alpha-reductase inhibiting compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-alpha-reductase. Also invented are novel ...
|
|
WO/1994/007908A1 |
A 7-substituted oxa- or azasteroid compound represented by general formula (I), which has an excellent aromatase-inhibiting effect and is useful for preventing or treating diseases caused by estrogens, such as breast cancer, uterine canc...
|
|
WO/1994/007909A1 |
The invention relates to novel 17beta-substituted 4-azaandrostane derivatives of general Formula (I), wherein R means hydrogen or a C1-3alkyl group; R1 and R2 are the same or different and stand for hydrogen or a C1-4alkyl group with the...
|
|
WO/1994/007861A1 |
Described are new 17beta-carboxanilides of 4-aza-5alpha-androstan-3-ones and related compounds and the use of such compounds as 5alpha-reductase inhibitors for treatment of benign prostatic hyperplasia and other hyperandrogenetic related...
|
|
WO/1994/007860A1 |
Described are new 17beta-aryl ester carboxylates of 4-aza-5alpha-androstan-3-ones and related compounds and the use of such compounds as 5alpha-reductase inhibitors for treatment of benign prostatic hyperplasia and other hyperandrogeneti...
|
|
WO/1994/006425A1 |
The compounds of formula (I) wherein R is selected from the group hydroxymethyl and carboxy, have been identified as metabolites of 5alpha-23-methyl-4-aza-21-nor-chol-1-ene-3,20-dione and are believed to be active as testosterone 5alpha-...
|
|
WO/1994/003474A1 |
The present invention concerns steroidic 5alpha-reductase inhibitors having formula (I), wherein the symbol -_-_-_-_ is a single or a double bond; A is a CH group or an N-R group wherein R is a hydrogen atom or a C1-C4 alkyl group provid...
|
|
WO/1994/003475A1 |
Compounds of formula (I), wherein: the symbol ._._._._ represents a single or a double bond; B is a bond or a straight or branched C1-C6 alkylene chain; R is hydrogen or C1-C4 alkyl; R1 is hydrogen, C1-C6 alkyl or benzyl; R2 is a) hydrog...
|
|
WO/1994/003476A1 |
A compound of formula (I), wherein R is a hydrogen atom or a C1-C4 alkyl group; A is a single bond or a straight or branched C1-C6 alkylene chain; R1 is a hydrogen atom or a C1-C6 alkyl group; R2 is a C1-C6 alkyl group, a C5-C7 cycloalky...
|
|
WO/1994/000121A1 |
Invented are 17alpha and 17beta-alkylketone-4-aza analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-alpha-reductase isozyme 1 an...
|
|
WO/1993/023038A1 |
Novel amino substituted 4-azasteroid 5alpha-reductase inhibitors of formula (I), wherein A is (a), (b) or (c), are claimed as well as pharmaceutically acceptable salts and formulations thereof. These compounds are effective in inhibiting...
|
|
WO/1993/023051A1 |
Described are new 17beta-ester, amide, and ketone 4-aza-5a-androstan-3-ones and related compounds and the use of such compounds as 5a-reductase inhibitors for treatment of benign prostatic hyperplasia and other hyperandrogenetic related ...
|
|
WO/1993/023041A1 |
Compounds of formula (I), wherein X is sulfur or oxygen are inhibitors of the 5alpha-reductase enzyme and isozymes thereof. The compounds are useful for the treatment of hyperandrogenic disease conditions and diseases of the skin and scalp.
|
|
WO/1993/023042A1 |
Invented are 17beta-substituted acyl-4-aza analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-alpha-reductase. Also invented are ...
|
|
WO/1993/023376A1 |
Described is a new process for producing 7beta-substituted-4-aza-5alpha-androstan-3-ones and related compounds which are 5alpha-reductase inhibitors, consisting of reducing the corresponding androsteneone with lithium and liquid ammonia,...
|
|
WO/1993/023050A1 |
Described are new delta-17 and delta-20 olefinic and saturated 17beta-substituted 4-aza-5alpha-androstan-3-ones and related compounds and the use of such compounds as 5alpha-reductase inhibitors for treatment of benign prostatic hyperpla...
|
|
WO/1993/023053A1 |
Inhibitors of testosterone 5alpha-reductase activity, for example those of formula (I) wherein novel substituents are provided at the R4, R6, R7, R17alpha and/or R17beta positions are useful for the treatment of diseases whose progress i...
|
|
WO/1993/023040A1 |
Compounds of formula (I), wherein Z contains an ether or thioether moiety, are inhibitors of the 5alpha-reductase enzyme and isozymes thereof. The compounds are useful for the treatment of hyperandrogenic disease conditions and diseases ...
|
|
WO/1993/023048A1 |
Novel substituted 4-azasteroid 5-alpha-reductase inhibitors of formula (I), wherein A is (a), (b) or (c), are claimed as well as pharmaceutically acceptable salts and formulations thereof. These compounds are effective inhibitors of test...
|
|
WO/1993/023420A1 |
Described are new 7beta-substituted 4-aza-5alpha-androstan-3-ones and related compounds as 5alpha-reductase inhibitors.
|
|
WO/1993/023039A1 |
Described are new 16-substituted and 7,16-disubstituted 4-aza-5alpha-androstan-3-ones and related compounds as 5alpha-reductase inhibitors.
|
|
WO/1993/023419A1 |
Described are new 7beta-substituted 4-aza-5alpha-cholestan-3-ones and related compounds as 5alpha-reductase inhibitors.
|
|
WO/1993/013124A1 |
The present invention relates to certain substituted 17$g(b)-substituted carbonyl-6-azaandrost-4-en-3-ones of formula (I), especially those of formula (IG) wherein R?1¿ and R?1¿ are: i) independently hydrogen or lower alkyl and the bon...
|
|
WO/1993/002096A1 |
The preparation of a compound of formula (I) wherein X is oxygen or sulphur; R1 is hydrogen or C1-C6 alkyl; each of R2 and R3 is, independently, hydrogen, C1-C6 alkyl, C5 or C6 cycloalkyl or C6-C9 cycloalkylalkyl; R4 is hydrogen, C1-C6 a...
|
|
WO/1992/017489A1 |
A compound represented by general formula (I), which has an aromatase inhibitory activity and is useful for preventing and treating diseases caused by hyperestrogenosis, such as mastocarcinoma, metrocarcinoma and prostatomegaly. In formu...
|
|
WO/1992/009618A1 |
Described are 8-ene-19, 11$g(b)-bridged steroids of general formula (I) which have a new structural feature in the form of a double bond between the 8 position and the 9 position. Also described is a method of preparing them. The substit...
|
|
WO/1992/000010A1 |
Invented is a method of treating human prostatic adenocarcinoma by employing a steroid 5-alpha-reductase inhibiting compound or a combination of steroid 5-alpha-reductase inhibiting compounds.
|
|
WO/1991/013903A1 |
The present invention relates to novel substituted 15-oxa-, 15-thia-, and 15-aza-dihydrolanosterols, to pharmaceutical compositions containing such compounds, and to methods of using these compounds to suppress the activity of 3-hydroxy-...
|
|
WO/1991/012206A2 |
Novel aromatase inhibitors are disclosed for use in therapeutic preparations for treatment of estrogen-dependent diseases. The compounds are specified 7alpha-substituted androstanedione and androstenedione derivatives which show a strong...
|
|
WO/1991/012261A1 |
The present invention concerns steroidic 5alpha-reductase inhibitors having formula (I) wherein R1 is hydrogen, a C1-C6 alkyl group, an aryl-C1-C6alkyl group, or an aroyl group; Y is oxygen or sulphur; W is a group (2) wherein each of R2...
|
|
WO/1991/001991A1 |
Introduction of a C-12 substituent and especially a beta C-12 substituent into glucocorticoids improves their usefulness as topical anti-inflammatories by increasing their topical activity relative to their systemic activity, thus reduci...
|
|
WO/1991/000732A1 |
Methods for treating sex steroid-dependent diseases by inhibiting sex steroid activity include administration of novel compounds which include an androgenic nucleus substituted at a ring carbon with at least one substituent specified her...
|
|
WO/1990/015045A1 |
The present invention is an oxidative process for the conversion of 21-unsaturated progesterones (I) to the corresponding 3,5-secoandrost-5-one-3,17$g(b)-dioic acids (II) by use of either ozone or an oxidizing agent, which are useful int...
|
|
JP2023145726A |
To provide aza, oxa and thia-pregnan-20-one-3α-ol compounds for use in treating CNS disorder.In some embodiments, the compounds are compounds of formula (I-Iea) or (I-Iea-1) or pharmaceutically acceptable salts thereof.SELECTED DRAWING:...
|
|
JP2023538424A |
This disclosure provides triptolide conjugates, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, as well as treatment of conditions/diseases such as those associated with cancer, im...
|
|
JP7295078B2 |
The present invention relates to novel steroidal compounds of formula (I), process for preparation of the same and composition comprising these compounds.
|
|
JP7241807B2 |
Provided is a crystalline polymorphic form A of 15²-hydroxy-osaterone acetate having an improved stability (storage stability, pulverization stability, and absorption characteristics). In a powder X-ray diffraction spectrum, characteris...
|
|
JP7210278B2 |
Provided is a crystalline polymorphic form A of 15²-hydroxy-osaterone acetate having an improved stability (storage stability, pulverization stability, and absorption characteristics). In a powder X-ray diffraction spectrum, characteris...
|
|
JP7148913B2 |
To provide a production method of a triterpenoid containing extract including at high density, triterpenoid such as limonoid that is simple and economical so that the method can be executed in an industrial scale.The invention provides a...
|
|
JP2022536698A |
Kind Code: A1 The present invention provides naturally occurring compounds, specifically guaurine A, B, C and D for use in medicine, which are non-cytotoxic and non-genotoxic to healthy lymphocytic cells. Kind Code: A1 Argentatin A and C...
|
|
JP7096559B2 |
Disclosed are a triptolide derivative and a preparation method therefor and the use thereof. The triptolide derivative has the structure as shown in general formula I, and the definition of each substituent is as described in the descrip...
|
|
JP2022500453A |
The present invention relates to formula (I) for the prophylactic or therapeutic treatment of fibrosis, non-alcoholic steatohepatitis (NAFLD), or non-alcoholic steatohepatitis (NASH):Provided is a compound thereof, or a pharmaceutically ...
|
|
JP6892278B2 |
Provided is a process for producing a compound, which has an oxo group specifically introduced on the 15-position of a steroid skeleton and which is useful as an intermediate, with a high yield without complicated steps. A compound repre...
|
|
JP2021512909A |
The present invention relates to a steroidal derivative modulator, a method for producing the same, and an application thereof. The present invention particularly relates to a compound represented by the general formula (I), a method for...
|
|
JP2021510695A |
Equation (II)Compounds or pharmaceutically acceptable salts thereof are provided herein and the variables are as defined herein. Pharmaceutical compositions comprising a compound of formula (II) and, for example, how to use the aforement...
|
